Publications by authors named "Juliet Liu"
Article Synopsis
- * A primary cause of resistance is mutations in the kinase domain, particularly solvent-front substitutions involving ALK, ROS1, and TRKC, which are challenging to overcome.
- * Repotrectinib is a next-generation TKI that has shown promise in clinical trials for patients previously treated with other TKIs, effectively targeting and overcoming resistance from these mutations.
Objective: The ability of erythropoietin (EPO) to elicit a pro-angiogenic effect on human mesenchymal stem cells (hMSC) was tested. hMSC are currently under study as therapeutic delivery agents that target tumor vessels. Hypoxia favors the differentiation of hMSC towards a pro-angiogenic program.
View Article and Find Full Text PDF